Ornal chemotherapy in colorectal cancer treatment: Review of the literature

European Journal of Internal Medicine

Volumn 14, Issue 1, 2003, Pages 18-25

  Kurtz, Jean Emmanuel ^a   Andrès, Emmanuel ^a   Natarajan Amé, Shanti ^a   Noel, Esther ^a   Dufour, Patrick ^a  

^a UNIVERSITY HOSPITAL OF STRASBOURG   (France)

Author keywords

Colorectal cancer; Oral chemotherapy; Treatment

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; 5 ETHYNYLURACIL; 9 AMINO 20 CAMPTOTHECIN; 9 AMINOCAMPTOTHECIN; 9 NITRO 20 CAMPTOTHECIN; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CAMPTOTHECIN DERIVATIVE; CAPECITABINE; CARMOFUR; DOXOFLURIDINE; FLOXURIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LEVAMISOLE; MITOMYCIN C; MMI 166; OXALIPLATIN; PLEVITREXED; PYRIMIDINE DERIVATIVE; RALTITREXED; RUBITECAN; TEGAFUR; UFT; UNCLASSIFIED DRUG; URACIL;

BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HUMAN; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; QUALITY OF LIFE; REVIEW; STOMATITIS; TREATMENT OUTCOME; VOMITING;

EID: 0037303731     PISSN: 09536205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0953-6205(02)00213-3     Document Type: Review

References (64)

1. Midgley R., Kerr D. Colorectal cancer. Lancet. 353:1999;391-399.
2. Midgley R., Kerr D. Conventional cytotoxic and novel therapeutic concepts in colorectal cancer. Exp Opin Invest Drugs. 10:2001;1011-1019.
3. Borner M., Scheithauer W., Twelves C., Maroun J., Wilke H. Answering patients' needs: oral alternatives to intravenous therapy. Oncologist. 6:(Suppl 4):2001;12-16.
4. Liu G., Franssen E., Fitch M.I., Warner E. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol. 15:1997;110-115.
5. Mayer R.J. Oral versus intravenous fluoropyrimidines for advanced colorectal cancer: by either route it's all the same. J Clin Oncol. 19:2001;4093-4096.
6. Kurtz J.E., Exinger F., Erbs P., Jund R. New insights into the pyrimidine salvage pathway of Saccharomyces cerevisiae: requirement of six genes for cytidine metabolism. Curr Genet. 36:1999;130-136.
7. Di Bartolomeo M., Bajetta E., Somma L., Buzzoni R. Doxifluridine: an active agent in advanced gastrointestinal cancer. Tumori. 81:(Suppl 3):1995;147-150.
8. Bajetta E., Colleoni M., Di Bartolomeo M., et al. Doxifluridine and leucovorin: an oral treatment combination in advanced colorectal cancer. J Clin Oncol. 13:1995;2613-2619.
9. Neri B., Gemelli M.T., Pantalone D., et al. Results of leucovorin and doxifluridine oral regimen in the treatment of metastatic colorectal cancer. Anticancer Drugs. 9:1998;599-602.
10. Seong J., Cho J.H., Kim N.K., Min J.S., Suh C.O. Preoperative chemoradiotherapy with oral doxifluridine plus low-dose oral leucovorin in unresectable primary rectal cancer. Int J Radiat Oncol Biol Phys. 50:2001;435-439.
11. Budman D.R., Meropol N.J., Reigner B., et al. Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine. J Clin Oncol. 16:1998;1795-1802.
12. Van Cutsem E., Findlay M., Osterwalder B., et al. Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study. J Clin Oncol. 18:2000;1337-1345.
13. Hoff P.M., Ansari R., Batist G., et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol. 19:2001;2282-2292.
14. Van Cutsem E., Twelves C., Cassidy J., et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol. 19:2001;4097-4106.
15. Twelves C., Boyer M., Findlay M., et al. Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma. Eur J Cancer. 37:2001;597-604.
16. Pitot H.C., Goldberg R.M. Future directions in adjuvant therapy for stage III colon carcinoma. Oncology (Huntingt). 15:(Suppl 5):2001;31-36.
17. Borner M.M., Mueller S., Roth A., et al. Phase II study of capecitabine (CAP)+oxaliplatin (OXA) in first line and second line treatment of advanced or metastatic colorectal cancer (ACC). Proc Am Soc Clin Oncol. 20:2001;137a.
18. DeSantis S., Zeuli M., Di Costanzo A., et al. Oxaliplatin and capecitabine in advanced colorectal cancer: a dose finding trial. Proc Am Soc Clin Oncol. 20:2001;141a.
19. Schleucher N., Tewes M., Achterrath W., et al. Extended phase I study of capecitabine in combination with a weekly schedule of irinotecan as first-line chemotherapy in metastatic colorectal cancer. Proc Am Soc Clin Oncol. 20:2001;141a.
20. Ito K., Yamaguchi A., Miura K., et al. Oral adjuvant chemotherapy with carmofur (HCFU) for colorectal cancer: 5-year follow-up. Tokai HCFU Study Group - third study on colorectal cancer. J Surg Oncol. 63:1996;107-111.
21. Nakamura T., Ohno M., Tabuchi Y., et al. Optimal duration of oral adjuvant chemotherapy with Carmofur in colorectal cancer patients: the Kansai Carmofur Study Group trial III. Int J Oncol. 19:2001;291-298.
22. Sakamoto J., Kodaira S., Hamada C., et al. An individual patient data meta-analysis of long supported adjuvant chemotherapy with oral carmofur in patients with curatively resected colorectal cancer. Oncol Rep. 8:2001;697-703.
23. Osterlund P., Elomaa I., Virkkunen P., Joensuu H. A phase I study of raltitrexed (tomudex) combined with carmofur in metastatic colorectal cancer. Oncology. 61:2001;113-119.
24. Taguchi T. Clinical application of biochemical modulation in cancer chemotherapy: biochemical modulation for 5-FU. Oncology. 54:(Suppl 1):1997;12-18.
25. Hoff P.M., Pazdur R. UFT plus oral Leucovorin: a new oral treatment for colorectal cancer. Oncologist. 3:1998;155-164.
26. Pazdur R., Lassere Y., Diaz-Canton E., Bready B., Ho D.H. Phase I trials of uracil-tegafur (UFT) using 5- and 28-day administration schedules: demonstration of schedule-dependent toxicities. Anticancer Drugs. 7:1996;728-733.
27. Pazdur R., Lassere Y., Rhodes V., et al. Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma. J Clin Oncol. 12:1994;2296-2300.
28. Saltz L.B., Leichman C.G., Young C.W., et al. A fixed-ratio combination of uracil and Ftorafur (UFT) with low dose leucovorin. An active oral regimen for advanced colorectal cancer. Cancer. 75:1995;782-785.
29. Gonzalez-Baron M., Feliu J., de la Gandara I., et al. Efficacy of oral tegafur modulation by uracil and leucovorin in advanced colorectal cancer. A phase II study. Eur J Cancer. 31A:1995;2215-2219.
30. Pazdur R. Phase II study of UFT plus leucovorin in colorectal cancer. Oncology. 54:(Suppl 1):1997;19-23.
31. Pazdur R., Royce M.E. Novel agents for colorectal cancer. Exp Opin Invest Drugs. 8:1999;1639-1652.
32. Carmichael J., Popiela T., Radstone D. Randomized comparative study of ORZEL (oral uracil/tegafur (UFT) plus leucovorin (LV)) versus parenteral 5-fluorouracil (5-FU) plus LV in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol. 18:1999;264a.
33. Sun W., Haller D. UFT in the treatment of colorectal and breast cancer. Oncology (Huntingt). 15:(Suppl 2):2001;49-56.
34. Douillard J.-Y., Hoff P.M., Skillings J.R., et al. Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 20:(17):2002;3605-3616.
35. Carmichael J., Popiela T., Radstone D., et al. Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 20:(17):2002;3617-3627.
36. Alonso V., Escudero P., Zorrilla M., et al. Phase I trial of weekly irinotecan combined with UFT as second-line treatment for advanced colorectal cancer. Eur J Cancer. 37:2001;2385-2391.
37. Price T., Hill M. UFT/leucovorin plus irinotecan in advanced or metastatic colorectal cancer. Oncology (Huntingt). 14:(Suppl 9):2000;28-31.
38. Ahmed F.Y., Johnston S.J., Cassidy J., et al. Eniluracil treatment completely inactivates dihydropyrimidine dehydrogenase in colorectal tumors. J Clin Oncol. 17:1999;2439-2445.
39. Schilsky R.L., Kindler H.L. Eniluracil: an irreversible inhibitor of dihydropyrimidine dehydrogenase. Exp Opin Invest Drugs. 9:2000;1635-1649.
40. Benson A.B. 3rd. Oral eniluracil/5-FU for advanced colon and breast carcinomas. Oncology (Huntingt). 15:(Suppl 2):2001;57-63.
41. Schilsky R.L., Bukowski R., Burris H. 3rd, et al. A multicenter phase II study of a five-day regimen of oral 5-fluorouracil plus eniluracil with or without leucovorin in patients with metastatic colorectal cancer. Ann Oncol. 11:2000;415-420.
42. Meropol N.J., Niedzwiecki D., Hollis D., Schilsky R.L., Mayer R.J. Phase II study of oral eniluracil, 5-fluorouracil, and leucovorin in patients with advanced colorectal carcinoma. Cancer. 91:2001;1256-1263.
43. Mani S., Hochster H., Beck T., et al. Multicenter phase II study to evaluate a 28-day regimen of oral fluorouracil plus eniluracil in the treatment of patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 18:2000;2894-2901.
44. Levin J., Schilsky R.L., Burris H., et al. North American phase III study of oral eniluracil (EU) plus oral-5-fluorouracil (5-FU) versus intravenous (IV) 5-FU plus leucovorin (LV) in the treatment of advanced colorectal cancer (ACC). Proc Am Soc Clin Oncol. 20:2001;132a.
45. Schilsky R.L., Levin J., West W.H., et al. Randomized, open-label, phase III study of a 28-day oral regimen of eniluracil plus fluorouracil versus intravenous fluorouracil plus leucovorin as first-line therapy in patients with metastatic/advanced colorectal cancer. J Clin Oncol. 20:(6):2002;1519-1526.
46. Van Cutsem E., Sorensen J., Cassidy J., et al. International phase III study of oral eniluracil (EU) plus 5-fluorouracil (5-FU) versus intravenous (IV) 5-fu plus leucovorin (LV) in the treatment of advanced colorectal cancer (ACC). Proc Am Soc Clin Oncol. 20:2001;131a.
47. Shirasaka T., Tsukuda M., Inuyama Y., Taguchi T. [New oral anticancer drug, TS-1 (S-1) - from bench to clinic]. Gan To Kagaku Ryoho. 28:(S-1):2001;855-864.
48. Sugimachi K., Maehara Y., Horikoshi N., et al. An early phase II study of oral S-1, a newly developed 5-fluorouracil derivative for advanced and recurrent gastrointestinal cancers. The S-1 Gastrointestinal Cancer Study Group. Oncology. 57:1999;202-210.
49. Ohtsu A., Baba H., Sakata Y., et al. Phase II study of S-1, a novel oral fluoropyrimidine derivative, in patients with metastatic colorectal carcinoma. S-1 Cooperative Colorectal Carcinoma Study Group. Br J Cancer. 83:2000;141-145.
50. Rothenberg M.L., Kuhn J.G., Schaaf L.J., et al. Alternative dosing schedules for irinotecan. Oncology (Huntingt). 12:(Suppl 6):1998;68-71.
51. Drengler R.L., Kuhn J.G., Schaaf L.J., et al. Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumors. J Clin Oncol. 17:1999;685-696.
52. De Jonge M.J., Punt C.J., Gelderblom A.H., et al. Phase I and pharmacologic study of oral (PEG-1000) 9-aminocamptothecin in adult patients with solid tumors. J Clin Oncol. 17:1999;2219-2226.
53. Giovanella B.C., Stehlin J.S., Hinz H.R., Kozielski A.J., Harris N.J., Vardeman D.M. Preclinical evaluation of the anticancer activity and toxicity of 9-nitro-20(S)-camptothecin (Rubitecan). Int J Oncol. 20:2002;81-88.
54. Konstadoulakis M.M., Antonakis P.T., Tsibloulis B.G., et al. A phase II study of 9-nitrocamptothecin in patients with advanced pancreatic adenocarcinoma. Cancer Chemother Pharmacol. 48:2001;417-420.
55. Niculescu-Duvaz I. ZD-9331 Astra Zeneca. Curr Opin Invest Drugs. 1:2000;141-149.
56. Oba K., Konno H., Tanaka T., et al. Prevention of liver metastasis of human colon cancer by selective matrix metalloproteinase inhibitor MMI-166. Cancer Lett. 175:2002;45-51.
57. Ohta M., Konno H., Tannaka T., et al. Effect of combination therapy with matrix metalloproteinase inhibitor MMI-166 and mitomycin C on the growth and liver metastasis of human colon cancer. Jpn J Cancer Res. 92:2001;688-695.
58. Glynne-Jones R., Debus J. Improving chemoradiotherapy in rectal cancer. Oncologist. 6:(Suppl 4):2001;29-34.
59. Fernandez-Martos C., Aparicio J., Bosch C., Torregrosa D., Campos J., Vicent J. Pre-operative therapy (PT) with oral uracil and tegafur (UFT) and concomitant irradiation (RT) in operable rectal cancer (RC). Preliminary results of a multicenter phase II study. Proc Am Soc Clin Oncol. 20:2001;148a.
60. Rosenthal D.I., Haller D.G., Saltz L., Semple D., Minsky B.D. Postoperative radiation therapy for rectal cancer combined with UFT/leucovorin. Oncology (Huntingt). 14:(Suppl 9):2000;59-62.
61. Hoff P.M., Saad E.D., Janjan N., Skibber J., Pazdur R. A phase I study. Preoperative UFT/leucovorin and radiation therapy in rectal cancer. Oncology (Huntingt). 14:(Suppl 9):2000;56-58.
62. Dunst J., Reese T., Frings S. Phase I study of capecitabine combined with simultaneous radiotherapy in rectal cancer. Proc Am Soc Clin Oncol. 20:2001;149a.
63. Ngan S., Zalcberg J., Kell A., et al. A phase I study of capecitabine combined with radiotherapy for locally advanced potentially operable rectal cancer. Proc Am Soc Clin Oncol. 20:2001;149a.
64. Amorino G.P., Hercules S.K., Mohr P.J., Pyo H., Choy H. Preclinical evaluation of the orally active camptothecin analog, RFS-2000 (9-nitro-20(S)-camptothecin) as a radiation enhancer. Int J Radiat Oncol Biol Phys. 47:2000;503-509.